Aridis Pharmaceuticals Alpha and Beta Analysis
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aridis Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aridis Pharmaceuticals over a specified time horizon. Remember, high Aridis Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aridis Pharmaceuticals' market risk premium analysis include:
Beta 0.9 | Alpha 1.11 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aridis |
Aridis Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aridis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Aridis Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aridis Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aridis Pharmaceuticals' performance over market.| α | 1.11 | β | 0.90 |
Aridis Pharmaceuticals Fundamentals Vs Peers
Comparing Aridis Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aridis Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Aridis Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aridis Pharmaceuticals or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Aridis Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Aridis Pharmaceuticals to competition |
| Fundamentals | Aridis Pharmaceuticals | Peer Average |
| Return On Asset | -1.08 | -0.14 |
| Operating Margin | (9.58) % | (5.51) % |
| Current Valuation | 12.11 M | 16.62 B |
| Shares Outstanding | 36.21 M | 571.82 M |
| Shares Owned By Insiders | 31.53 % | 10.09 % |
| Shares Owned By Institutions | 11.60 % | 39.21 % |
| Number Of Shares Shorted | 2 M | 4.71 M |
Aridis Pharmaceuticals Opportunities
Aridis Pharmaceuticals Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Aridis Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aridis or other pink sheets. Alpha measures the amount that position in Aridis Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Aridis Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Aridis Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aridis Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aridis Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aridis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Aridis Pharmaceuticals' management manipulating its earnings.
| 15th of August 2023 Upcoming Quarterly Report | View | |
| 20th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aridis Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |